Showing results (371-380 of 379) with videos related to
Sort By:
Pageof 38
You have reached the last page of results.This site can display upto 379 results.
Journal of Parkinson'S Disease|May 24, 2020
Recommendations for the Organization of Multidisciplinary Clinical Care Teams in Parkinson's DiseaseDanique L M Radder, Jorik Nonnekes, Marlies van Nimwegen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2025
Nivolumab and Relatlimab for the treatment of patients with unresectable or metastatic mismatch repair proficient colorectal cancerEric S Christenson, Won Jin Ho, Daniel Shu, et al.Journal of the National Comprehensive Cancer Network : JNCCN|September 22, 2021
NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021Efrat Dotan, Louise C Walter, Ilene S Browner, et al.Journal of Medicinal Chemistry|March 3, 2006
Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinaseDavid M Goldstein, Tom Alfredson, Jay Bertrand, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2016
NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016Noam VanderWalde, Reshma Jagsi, Efrat Dotan, et al.Journal of the National Comprehensive Cancer Network : JNCCN|January 24, 2014
Senior adult oncology, version 2.2014: clinical practice guidelines in oncology Arti Hurria, Tanya Wildes, Sarah L Blair, et al.Bioorganic & Medicinal Chemistry Letters|November 16, 2010
A novel series of IKKβ inhibitors part II: description of a potent and pharmacologically active series of analogsTimothy D Cushing, Vijay Baichwal, Karen Berry, et al.Bioorganic & Medicinal Chemistry Letters|November 16, 2010
A novel series of IKKβ inhibitors part I: Initial SAR studies of a HTS hitTimothy D Cushing, Vijay Baichwal, Karen Berry, et al.Journal of Medicinal Chemistry|December 11, 2012
3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo modelsMichael Soth, Johannes C Hermann, Calvin Yee, et al.Pageof 38